| ISSN |
2220-3206 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Psychiatry |
| Manuscript Type |
Observational Study |
| Article Title |
Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yu-Mei Wei, Xi-Jin Wang, Xiao-Dong Yang, Chuan-Sheng Wang, Li-Li Wang, Xiao-Ying Xu, Gui-Jun Zhao, Bin Li, Dao-Min Zhu, Qi Wu and Yi-Feng Shen |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Collaborative Innovation Center Project of Translational Medicine, Shanghai Jiaotong University School of Medicine |
TM202116PT (2021-2023) |
| Clinical Research Plan of SHDC |
SHDC2022CRS032 |
| the Sumitomo Pharmaceuticals (Suzhou) Co., Ltd |
|
|
| Corresponding Author |
Yi-Feng Shen, MD, PhD, Professor, Shanghai Key Laboratory of Psychotic Disorders, Shanghai Clinical Research Center for Mental Health, Shanghai Jiao Tong University, No. 600 Wanping Nan Road, Shanghai 200030, China, Shanghai 200030, China. shenyifeng@sina.com |
| Key Words |
Lurasidone; Safety; Effectiveness; Surveillance; Schizophrenia; Chinese |
| Core Tip |
We conducted the first post-marketing surveillance of the actual use of lurasidone in the treatment of patients with schizophrenia in real-world clinical practice since the drug was licensed in mainland China in 2019, and evaluated the safety profile and effectiveness of lurasidone in Chinese population. Here, we report an interim analysis based on 965 patients who received the medication between 2019 and 2022. This study hold significance as it contributes additional safety and effectiveness data on lurasidone beyond what was gathered in pre-marketing trials. Furthermore, it provides valuable reference information for clinical decision-making of schizophrenia treatment. |
| Publish Date |
2023-11-17 09:20 |
| Citation |
Wei YM, Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM, Wu Q, Shen YF. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World J Psychiatry 2023; 13(11): 937-948 |
| URL |
https://www.wjgnet.com/2220-3206/full/v13/i11/937.htm |
| DOI |
https://dx.doi.org/10.5498/wjp.v13.i11.937 |
